Mexico

BMI View: Genomma Lab Internacional's double-digit net sales growth in Q112 has not revived its recent share price deterioration, which reflects investors' disappointment over the results... 2012-05-01

BMI View: Pharmaceutical companies will benefit from new rules brought in by the government in Mexico for the approval of biological products, the aim of which is to strengthen Mexico's... 2012-04-23

BMI View: Mexican pharmaceutical companies will benefit from the expansion of production capacity and investment in research and development (R&D), initially to meet stronger domestic-market... 2012-04-18

BMI View: Multinational pharmaceutical companies will benefit from the stronger pharmaceutical market growth in Mexico. We particularly highlight the outperforming generic medicine... 2012-04-17

BMI View: Many emerging markets have become increasingly important for the launch of new drugs as they have established firm growth during the past few years. It is crucial for multinational... 2012-04-04

BMI View: Multinational pharmaceutical companies will be able to benefit from strong pharmaceutical market growth in Mexico and capitalise on the outperforming generic drug sector,... 2012-03-09

BMI View: Mexico's authorities should introduce strict pharmaceutical traceability systems to tackle the widespread prevalence of counterfeit drugs and medical samples on the black... 2012-03-01

BMI View: Latin American drugmakers who previously focused on a domestic market should be cautious with territorial and product expansion abroad due to the inherent differences in operating... 2012-02-28

BMI Core View: The generic drug industry will stratify into the following subsectors: unbranded/commodity generics; branded generics; value-added generics; and hard-to-manufacture generics.... 2012-02-21

BMI View: The unattractiveness of Mexico's pharmaceutical market is driving local producers to seek opportunities in Brazil. We believe that as the region's most attractive market,... 2012-02-17